Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Gould Rothberg BE, Bracken MB, Rimm DL.

J Natl Cancer Inst. 2009 Apr 1;101(7):452-74. doi: 10.1093/jnci/djp038. Epub 2009 Mar 24. Review.

2.

Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.

Jamieson NB, Carter CR, McKay CJ, Oien KA.

Clin Cancer Res. 2011 May 15;17(10):3316-31. doi: 10.1158/1078-0432.CCR-10-3284. Epub 2011 Mar 28. Review.

3.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer.

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

PMID:
16595783
4.

Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis.

Zhao L, Yu N, Guo T, Hou Y, Zeng Z, Yang X, Hu P, Tang X, Wang J, Liu M.

Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1047-54. doi: 10.1158/1055-9965.EPI-13-0696. Epub 2014 Mar 17. Review.

5.

Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.

Nielsen PS, Riber-Hansen R, Jensen TO, Schmidt H, Steiniche T.

Mod Pathol. 2013 Mar;26(3):404-13. doi: 10.1038/modpathol.2012.188. Epub 2012 Nov 23.

6.

Melanoma prognostic model using tissue microarrays and genetic algorithms.

Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger HM, Rimm DL.

J Clin Oncol. 2009 Dec 1;27(34):5772-80. doi: 10.1200/JCO.2009.22.8239. Epub 2009 Nov 2.

7.

Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.

Kyrgidis A, Tzellos T, Mocellin S, Apalla Z, Lallas A, Pilati P, Stratigos A.

Cochrane Database Syst Rev. 2015 May 16;(5):CD010307. doi: 10.1002/14651858.CD010307.pub2. Review.

PMID:
25978975
8.

Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.

Lade-Keller J, Riber-Hansen R, Guldberg P, Schmidt H, Hamilton-Dutoit SJ, Steiniche T.

J Clin Pathol. 2014 Jun;67(6):520-8. doi: 10.1136/jclinpath-2013-202127. Epub 2014 Mar 7.

PMID:
24607493
9.

Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

BMC Cancer. 2010 Apr 14;10:140. doi: 10.1186/1471-2407-10-140.

10.

Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.

Nielsen PS, Riber-Hansen R, Schmidt H, Steiniche T.

Diagn Pathol. 2016 Apr 9;11:35. doi: 10.1186/s13000-016-0484-4.

11.

Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.

Harcharik S, Bernardo S, Moskalenko M, Pan M, Sivendran M, Bell H, Hall LD, Castillo-Martín M, Fox K, Cordon-Cardo C, Chang R, Sivendran S, Phelps RG, Saenger Y.

J Am Acad Dermatol. 2014 Jun;70(6):1036-44. doi: 10.1016/j.jaad.2014.01.914. Epub 2014 Mar 31.

PMID:
24698703
12.

Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.

Donizy P, Zietek M, Halon A, Leskiewicz M, Kozyra C, Matkowski R.

Diagn Pathol. 2015 Jul 2;10:86. doi: 10.1186/s13000-015-0331-z.

13.

High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.

Nodin B, Fridberg M, Jonsson L, Bergman J, Uhlén M, Jirström K.

Diagn Pathol. 2012 Jul 17;7:82. doi: 10.1186/1746-1596-7-82.

14.

Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma.

Tetzlaff MT, Curry JL, Ivan D, Wang WL, Torres-Cabala CA, Bassett RL, Valencia KM, McLemore MS, Ross MI, Prieto VG.

Mod Pathol. 2013 Sep;26(9):1153-60. doi: 10.1038/modpathol.2013.59. Epub 2013 Apr 5.

15.

Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker.

Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD.

Plast Reconstr Surg. 2005 Feb;115(2):367-75.

PMID:
15692338
16.

Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.

Murali R, Haydu LE, Long GV, Quinn MJ, Saw RP, Shannon K, Spillane AJ, Stretch JR, Kefford RF, Thompson JF, Scolyer RA.

Ann Surg Oncol. 2012 Jun;19(6):1782-9. doi: 10.1245/s10434-012-2265-y. Epub 2012 Feb 14.

PMID:
22350600
17.

Sequential molecular analysis of circulating MCAM/MUC18 expression: a promising disease biomarker related to clinical outcome in melanoma.

Rapanotti MC, Suarez Viguria TM, Costanza G, Ricozzi I, Pierantozzi A, Di Stefani A, Campione E, Bernardini S, Chimenti S, Orlandi A, Bianchi L.

Arch Dermatol Res. 2014 Aug;306(6):527-37. doi: 10.1007/s00403-014-1473-7. Epub 2014 Jun 7.

18.

Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Gould Rothberg BE, Rimm DL.

J Invest Dermatol. 2010 Aug;130(8):1971-87. doi: 10.1038/jid.2010.149. Epub 2010 Jun 17.

19.

Novel role for RGS1 in melanoma progression.

Rangel J, Nosrati M, Leong SP, Haqq C, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M.

Am J Surg Pathol. 2008 Aug;32(8):1207-12. doi: 10.1097/PAS.0b013e31816fd53c.

PMID:
18580492
20.

Triple-marker PCR assay of sentinel lymph node as a prognostic factor in melanoma.

Ito T, Wada M, Nagae K, Nakano-Nakamura M, Nakahara T, Hagihara A, Furue M, Uchi H.

J Eur Acad Dermatol Venereol. 2015 May;29(5):912-8. doi: 10.1111/jdv.12722. Epub 2014 Sep 8.

PMID:
25199412

Supplemental Content

Support Center